Srs Formulations Profile
Key Indicators
- Authorised Capital ₹ 70.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 46.15 Cr
as on 22-12-2024
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 12.00 Cr
as on 22-12-2024
- Revenue %
(FY 2020)
- Profit -2264.70%
(FY 2020)
- Ebitda -94.77%
(FY 2020)
- Net Worth -10.62%
(FY 2020)
- Total Assets 5.82%
(FY 2020)
About Srs Formulations
The Corporate was formerly known as Adkure Technologies Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 70.00 Cr and a paid-up capital of Rs 46.15 Cr.
The company has closed loans amounting to ₹12.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Srs Formulations Private Limited India is Komal Jain as COMPANY SECRETARY. Manoj Sharma and Kishen Kaul serve as directors at the Company.
- CIN/LLPIN
U74999MH2014PTC255945
- Company No.
255945
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Srs Formulations?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Komal Jain | Company Secretary | 05-Sep-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Sharma  | Director | 26-Dec-2022 | Current |
| Kishen Kaul | Director | 10-Nov-2023 | Current |
Financial Performance of Srs Formulations.
Srs Formulations Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 2264.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srs Formulations?
In 2019, Srs Formulations had a promoter holding of 76.00% and a public holding of 24.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 17 Feb 2017 | ₹12.00 Cr | Satisfied |
How Many Employees Work at Srs Formulations?
Unlock and access historical data on people associated with Srs Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srs Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srs Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
